The authors concluded that in their analysis of real-world data, the effectiveness of the biosimilar was equivalent to that of the reference product in patients with Crohn disease (CD) who were naïve to therapy with infliximab, and no difference was observed in terms of safety between the 2 therapies.
Celltrion’s CT-P13, an infliximab biosimilar approved in the United States as Inflectra and in the European Union as Remsima, is widely used in the treatment of inflammatory diseases, and was approved on the basis of studies conducted in rheumatoid arthritis and ankylosing spondylitis.
An extrapolated indication was granted for the treatment of Crohn disease (CD), and since approval, numerous real-world data have supported the use of CT-P13 in patients with CD. A new study, published this week in Annals of Internal Medicine, further underscores the safety and effectiveness of CT-P13 in this disease state.
The comparative equivalence cohort study compared CT-P13 with the reference infliximab, Remicade, in patients with CD who were naïve to infliximab therapy. In total, 5050 patients aged 15 years or older were enrolled in the study, and 2551 were given the reference infliximab, while 2499 were given the biosimilar. None of the patients had other diseases with an indication for treatment with infliximab.
The study’s primary outcome was a composite end point of death, CD-related surgery, all-cause hospitalization, and reimbursement for another biologic treatment. The predefined equivalence margin (0.80-1.25) was defined as a 95% CI of the hazard ratio (HR) of CT-P13 versus the reference product in a multivariable marginal Cox model.
In total, 1147 patients in the reference group met the composite end point, with 838 hospitalizations. In the biosimilar group, 952 patients, with 719 hospitalizations, met the end point. In a multivariable analysis, CT-P13 was equivalent to the reference infliximab, with an HR of 1.10 (95% CI, 0.26-3.34).
There were no differences in safety outcomes between the 2 groups with respect to serious infection (HR, 0.82; 95% CI, 0.61-1.11), tuberculosis (HR, 1.10; 95% CI, 0.36-3.34), or malignancy (HR, 0.66; 95% CI, 0.33-1.32).
The authors concluded that in their analysis of the real-world data, the effectiveness of the biosimilar was equivalent to that of the reference product in patients with CD who were naïve to therapy with infliximab, and no difference was observed in terms of safety between the 2 therapies.
Reference
Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study [published online December 11, 2018]. Ann Intern Med. doi: 10.7326/M18-1512.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Gastroenterology Roundup: November 2024
November 30th 2024In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms grew; Celltrion expanded its portfolio; and Global Biosimilars Week focused on improving affordability and equity.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy
November 23rd 2024In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.